Literature DB >> 11008860

Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment.

K Järventausta1, E Leinonen.   

Abstract

OBJECTIVE: To date only five reports of neuroleptic malignant syndrome (NMS) related to olanzapine exist. The first case report was published in November 1998.
METHOD: We report the case of a 78-year-old woman suffering from chronic schizophrenia who developed a NMS while being treated with olanzapine and levomepromazine. Before this her medication had been unchanged for more than 2 years.
RESULTS: When treated with olanzapine and levomepromazine, the patient had a fulminant NMS which was complicated with pneumonia. When the neuroleptic drug treatment was discontinued, the patient recovered. However, when this combination was restarted later due to severe agitation and hallucinations, the symptoms of NMS reappeared.
CONCLUSION: This case report shows that the neuroleptic malignant syndrome can occur during olanzapine treatment as well as during treatment with conventional neuroleptics. This syndrome may develop even after a long and stable neuroleptic treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11008860     DOI: 10.1034/j.1600-0447.2000.102003231.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  3 in total

1.  An atypical case of neuroleptic malignant syndrome precipitated by valproate.

Authors:  Rajesh Verma; Vivek Junewar; Bhanu Pratap Singh Rathaur
Journal:  BMJ Case Rep       Date:  2014-03-06

2.  Neuroleptic malignant syndrome in an adolescent with CYP2D6 deficiency.

Authors:  Agnieszka Butwicka; Szymańska Krystyna; Włodzimierz Retka; Tomasz Wolańczyk
Journal:  Eur J Pediatr       Date:  2013-11-20       Impact factor: 3.183

3.  Olanzapine-associated neuroleptic malignant syndrome: Is there an overlap with the serotonin syndrome?

Authors:  Vassilis P Kontaxakis; Beata J Havaki-Kontaxaki; Nikolaos G Christodoulou; Konstantinos G Paplos; George N Christodoulou
Journal:  Ann Gen Hosp Psychiatry       Date:  2003-10-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.